Article Information
History
- November 22, 2024.
Article Versions
- You are currently viewing Version 1 of this article (November 22, 2024 - 22:43).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Shadisadat Esmaeili1,*,
- Katherine Owens1,
- Jessica Wagoner2,
- Stephen J. Polyak2,
- Shengyuan Zhang3,
- Joseph F. Standing3,4,
- David M. Lowe5,6 and
- Joshua T. Schiffer1,7
- 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
- 2Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA, USA
- 3Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK
- 4Great Ormond Street Hospital for Children NHS Trust, London, UK
- 5Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK
- 6Institute of Immunity and Transplantation, University College London, London, UK
- 7Department of Medicine, University of Washington; Seattle, WA, USA
- ↵*Corresponding Author: sesmaeil{at}fredhutch.org
Posted November 22, 2024.
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2
